Connect with us

Hi, what are you looking for?

Investing

Adicet Bio Down 54% After Reporting Data From Non-Hodgkin’s Lymphoma Study

By Josh Beckerman

Adicet Bio shares fell 54% to $2.15 on Tuesday after the company reported data from an ongoing Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma.

The company said Monday the safety and efficacy data were positive, and “these data are exciting and beyond what one might expect to see given that patients enrolled in the study were heavily pre-treated.”

However, JPMorgan Chase analyst Brian Cheng said “mixed” updates left “key questions unanswered.”

JMP Securities and Guggenheim lowered their ratings on Tuesday.


Write to Josh Beckerman at [email protected]


Read the full article here

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

News

Genesco Inc. (NYSE:GCO) Q3 2025 Earnings Conference Call December 6, 2024 8:30 AM ET Company Participants Darryl MacQuarrie – Senior Director of FP&AMimi Vaughn...

News

Listen below or on the go on Apple Podcasts and Spotify Handling market volatility with long-term dividend growth investing. Prioritizing future dividends over immediate...

News

This article was written by Follow Cash Builder Opportunities (aka Nick Ackerman) is a former fiduciary and a registered financial advisor with 14 years...

News

This article was written by Follow True Orion is comprised of two notions. Orion, the ancient mythical hunter, and truth. The neverending pursuit for...